drugset / Trial / NCT01727128

Pharmacokinetic Study of BKM120 in Subjects With Hepatic Impairment

NCT01727128

Phase 1 Completed 31 enrolled Novartis Pharmaceuticals
Non-randomizedCrossoverOpen-labelBasic science

Summary

To assess pharamcokinetics, safety and tolerability of a single oral dose of BKM120 in subjects with mild, moderate and severe hepatic impairment

Timeline

Start
2011-10
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Buparlisib Small molecule Oral

Indications

No indication recorded.